Colby Pharmaceutical Company, a clinical stage drug development company organized around non-toxic signal transduction and hypoxia inhibitor drug therapeutics specifically targeting survival pathways in solid tumor cells, immune or immune suppressed cells, and vas-occlusive conditions. The firm has developed a proprietary system for direct Intra Lymph Node Injection (ILNI). This ILNI Platform Technology has been developed for allergy desensitization, cancer immunotherapy and infectious disease vaccination. In collaboration with others, Colby is working on developing anti-inflammatory, -cancer and -autoimmune disease therapeutics. With clinical research professionals, the firmis achieving human safety and efficacy in solid or hematological malignancies treated with proprietary cancer-specific targeted agents, using novel intralymphnode and other advanced delivery technologies resulting in significant long-term durable cancer patient remissions and potential cures. The firm's anti-inflammatory medicines are molecularly-targeted small molecule-, bio- and immuno-therapeutics advancing cost-effective clinical practices and favorable patient outcomes. Colby's molecularly targeted agents treat chronic inflammatory or hyper-proliferative diseases and are expanding clinical applications beyond cancer into targeted allergy, pain, regenerative and auto-immune medicines.
